Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Transcode Therapeutics Inc RNAZ

Healthcare Biotechnology
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Company’s pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.


NDAQ:RNAZ - Post by User

Transcode Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(169)
•••
Post by whytestockson Jun 10, 2024 10:00am
32 Views
Post# 36080688

Nasdaq Determines That TransCode Therapeutics Has Regained C

Nasdaq Determines That TransCode Therapeutics Has Regained C
News; $RNAZ Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing RequirementsBOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the &#x201C;Company&#x201D;), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from the NASDAQ Stock Market LLC (Nasdaq)...RNAZ - Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities